Compare ALTI & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALTI | FULC |
|---|---|---|
| Founded | 2020 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 394.0M | 468.1M |
| IPO Year | N/A | 2019 |
| Metric | ALTI | FULC |
|---|---|---|
| Price | $5.19 | $13.00 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $16.38 |
| AVG Volume (30 Days) | 156.1K | ★ 2.6M |
| Earning Date | 11-12-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $226,717,000.00 | N/A |
| Revenue This Year | $19.78 | N/A |
| Revenue Next Year | $7.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2752.05 |
| 52 Week Low | $2.33 | $2.32 |
| 52 Week High | $5.45 | $15.74 |
| Indicator | ALTI | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 78.03 | 61.65 |
| Support Level | $4.29 | $12.56 |
| Resistance Level | $5.45 | $15.32 |
| Average True Range (ATR) | 0.33 | 1.27 |
| MACD | 0.13 | 0.30 |
| Stochastic Oscillator | 85.92 | 60.90 |
AlTi Global Inc is an independent wealth and asset manager providing entrepreneurs, multi-generational families, institutions, and emerging next-generation leaders with fiduciary capabilities as well as alternative investment strategies and advisory services. The firm has business which is organized into two business segments namely: Wealth & Capital Solutions and the International Real Estate segment includes providing holistic solutions for wealth management clients through comprehensive range of wealth management services, including investment management and advisory services. International Real Estate segment includes assist investors with real estate co-investments, structuring and selecting partners with a track record with risk adjusted return characteristics.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.